Neurology

The Pharmacy Times® Neurology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
[[thumbnail_alt_text]]
After up to 4.8 years of treatment with nusinersen, 100% of children with spinal muscular atrophy (SMA) who were treated pre-symptomatically are still alive.
 
[[thumbnail_alt_text]]
The researchers identified 87 articles using the PubMed and PsycINFO databases and the 2017 American Academy of Neurology (AAN) criteria for therapeutic trials.
[[thumbnail_alt_text]]
The authors posited that teriflunomide could prevent an excessive immune response while still maintaining enough defense against the virus.
[[thumbnail_alt_text]]
SE requires prompt intervention to terminate seizure activity to prevent neuronal damage and complications.
[[thumbnail_alt_text]]
Galcanezumab-gnlm (Emgality, Lilly) has received FDA-approval for the preventive treatment of migraine in adults and for the treatment of episodic cluster headache in adults.
 
[[thumbnail_alt_text]]
As Alzheimer disease research evolves beyond targeting a single pathology, interventions should coordinate disease stage with pathology and the patient’s presenting characteristics.
 
[[thumbnail_alt_text]]
According to a recent study, people with a higher risk of cardiovascular disease demonstrate an increase in cognitive decline, including a rise in the typical markers of Alzheimer disease.
[[thumbnail_alt_text]]
New treatment options offer hopes of better clinical outcomes for patients suffering from Parkinson disease and its debilitating daily symptoms.
[[thumbnail_alt_text]]
Dihydroergotamine Mesylate Nasal Spray is FDA-approved as therapeutic equivalent to Migranal.
[[thumbnail_alt_text]]
Telemedicine and connected devices are emerging as technologies to provide greater access and convenience to care for those who can defer treatment by way of an in-person consultation.
[[thumbnail_alt_text]]
The recommended dosage of lemborexant CIV is one 5 mg tablet taken no more than once per night, immediately before going to bed with at least 7 hours remaining before the planned time of awakening.
[[thumbnail_alt_text]]
Ensuring patients continue receiving life-sustaining home infusions that were traditionally administered in the hospital or hospital clinic settings is of the upmost importance.